David A Six

Years Active: 2017-2023
Publications (10 Years): 5

Venatorx Pharmaceuticals (United States)

University of California, San Diego (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Venatorx Pharmaceuticals (United States)

United States

Principal Scientist :: Biology

Education History

University of California, San Diego

United States

PHD :: Chemistry and Biochemistry

Publications

María Fernanda Mojica, Elise T Zeiser, Scott A Becka, John J LiPuma, David A Six, Greg Moeck, Krisztina M Papp-Wallace
Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial agents and chemotherapy (2023)
Phillip E Klebba, Salete M C Newton, David A Six, Ashish Kumar, Taihao Yang, Brittany L Nairn, Colton Munger, Somnath Chakravorty
Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics. Chemical reviews 121 (9) (2021)
Elyse J Roach, Tsuyoshi Uehara, Denis M Daigle, David A Six, Cezar M Khursigara
The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Microbiology spectrum 9 (2) (2021)
Marcella Widya, William D Pasutti, Meena Sachdeva, Robert L Simmons, Pramila Tamrakar, Thomas Krucker, David A Six
Development and Optimization of a Higher-Throughput Bacterial Compound Accumulation Assay. ACS infectious diseases 5 (3) (2019)
Inga Nilsson, Kerri Grove, Dustin Dovala, Tsuyoshi Uehara, Guillaume Lapointe, David A Six
Molecular characterization and verification of azido-3,8-dideoxy-d-manno-oct-2-ulosonic acid incorporation into bacterial lipopolysaccharide. The Journal of biological chemistry 292 (48) (2017)

David A Six.css-eqlu8i{font-size:small;padding-left:4px;}